EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

METTL1/FOXM1 promotes lung adenocarcinoma progression and gefitinib resistance by inhibiting PTPN13 expression

Wei Peng iD, Jia Fu, Lijun Zhou, Huaxin Duan

Cancer Medicine · 2024-07 · 13 (13)

DOI: 10.1002/cam4.7420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 05.07.2024. Verfasst von Wei Peng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hunan Provincial People's Hospital, The First Affiliated of Human Normal University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Forkhead Box Protein M1, Drug Resistance, Neoplasm, Gefitinib, Adenocarcinoma of Lung. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Changsha Natural Science Foundation, This study was supported by the National Natural Science Foundation of China, The Hunan Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lung adenocarcinoma (LUAD) is the most common malignant tumor in respiratory system. Methyltransferase‐like 1 (METTL1) is a driver of m7G modification in mRNA. This study aimed to demonstrate the role of METTL1 in the proliferation, invasion and Gefitinib‐resistance of LUAD.

Methods

Public datasets were downloaded from the Gene Expression Profiling Interactive Analysis (GEPIA) and GSE31210 datasets. Malignant tumor phenotypes were tested in vitro and in vivo through biological function assays and nude mouse with xenograft tumors. RNA immunoprecipitation assays were conducted to determine the interaction between METTL1 protein and FOXM1 mRNA. Public transcriptional database, Chromatin immunoprecipitation and luciferase report assays were conducted to detect the downstream target of a transcriptional factor FOXM1. Half maximal inhibitory concentration (IC50) was calculated to evaluate the sensitivity to Gefitinib in LUAD cells.

Results

The results showed that METTL1 was upregulated in LUAD, and the high expression of METTL1 was associated with unfavorable prognosis. Through the m7G‐dependent manner, METTL1 improved the RNA stability of FOXM1, leading to the up‐regulation of FOXM1. FOXM1 transcriptionally suppressed PTPN13 expression. The METTL1/FOXM1/PTPN13 axis reduced the sensitivity of LUAD cells to Gefitinib. Taken together, our data suggested that METTL1 plays oncogenic role in LUAD through inducing the m7G modification of FOXM1, therefore METTL1 probably is a new potential therapeutic target to counteract Gefitinib resistance in LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Forkhead Box Protein M1Drug Resistance, NeoplasmGefitinibAdenocarcinoma of LungLung NeoplasmsMethyltransferasesGene Expression Regulation, NeoplasticMice, NudeHumansAnimalsMiceCell Line, TumorCell ProliferationXenograft Model Antitumor AssaysDisease ProgressionFemaleMice, Inbred BALB CPrognosisAntineoplastic Agents

Stichwörter der Autor:innen

METTL1PTPN13gefitiniblung adenocarcinomaprogression

Substanzen

Forkhead Box Protein M1GefitinibMethyltransferasesFOXM1 protein, humanMETTL1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, Hunan Provincial People's Hospital, The First Affiliated of Human Normal University, Changsha, Hunan, China.
  • Key Laboratory of Study and Discovey of Small Targeted Molecules of Hunan Province, Hunan Normal University, Changsha, Hunan, China.
  • Laboratory of Oncology, Institute of Translational Medicine, Hunan Procincial People's Hospital, Changsha, Hunan, China.

ORCID-Profile: Wei Peng

Förderung

  • The Changsha Natural Science Foundation
  • This study was supported by the National Natural Science Foundation of China
  • The Hunan Natural Science Foundation
  • Natural Science Foundation of Hunan Province

Zitieren

APA

Peng, W., Fu, J., Zhou, L., & Duan, H. (2024). METTL1/FOXM1 promotes lung adenocarcinoma progression and gefitinib resistance by inhibiting PTPN13 expression. Cancer Medicine, 13(13). https://doi.org/10.1002/cam4.7420

Vancouver

Peng W, Fu J, Zhou L, Duan H. METTL1/FOXM1 promotes lung adenocarcinoma progression and gefitinib resistance by inhibiting PTPN13 expression. Cancer Medicine. 2024;13(13). doi:10.1002/cam4.7420

BibTeX
@article{Peng2024,
  author = {Peng, Wei and Fu, Jia and Zhou, Lijun and Duan, Huaxin},
  title = {METTL1/FOXM1 promotes lung adenocarcinoma progression and gefitinib resistance by inhibiting PTPN13 expression},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {13},
  doi = {10.1002/cam4.7420}
}
Kostenlos starten →